UCSF-CAPRA Prostate Cancer Risk Score

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۱۰۰۰ • واحد: ng/mL

حداقل ۳۰ — حداکثر ۱۱۰ • واحد: years

حداقل ۰ — حداکثر ۱۰۰ • واحد: %

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
capra total
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low risk0–2
  • Intermediate risk3–5
  • High risk6–10
Direct Clinical Answer

The UCSF-CAPRA Prostate Cancer Risk Score calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include psa. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

UCSF Cancer of the Prostate Risk Assessment (CAPRA, Cooperberg 2005): 0-10 point preoperative score predicting prostate cancer recurrence/ progression risk from PSA, Gleason pattern, clinical stage, age, and percent positive biopsy cores. 0-2 low, 3-5 intermediate, 6-10 high risk.

Clinical Indication

The UCSF-CAPRA Prostate Cancer Risk Score is indicated for bedside clinical practice to support UCSF Cancer of the Prostate Risk Assessment (CAPRA, Cooperberg 2005): 0-10 point preoperative score predicting prostate cancer recurrence/ progression risk from PSA, Gleason pattern, clinical stage, age, and percent positive biopsy cores. 0-2 low, 3-5 intermediate, 6-10 high risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

CAPRA = PSA(≤6:0, 6.1-10:1, 10.1-20:2, 20.1-30:3, >30:4) + Gleason(no 4/5:0, secondary 4/5:1, primary 4/5:3) + stage(T1/T2:0, T3a:1) + age(<50:0, ≥50:1) + pos cores(<34%:0, ≥34%:1)

Input Parameters

NameTypeRequiredDescription
psafloatYesPSA at diagnosis(ng/mL)
gleason_patternstringYesGleason pattern 4 or 5
clinical_stagestringYesClinical T stage
ageintegerYesAge in years(years)
percent_positive_coresfloatYesPercent of biopsy cores positive(%)

Score Interpretation & Guidance

RangeStageDescription
0–2Low riskLow risk
3–5Intermediate riskIntermediate risk
6–10High riskHigh risk

Evidence-Based References (EBM)

  • Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938-1942.

Related calculators